Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Cerebral vasospasm following subarachnoid hemorrhage (SAH) is the most common cause of morbidity and mortality. Recent studies indicate that Rho-kinase play an important role in the occurrence of such cerebral vasospasm. Eicosapentaenoic acid (EPA) inhibits sphingosylphosphorylcholine (SPC)-induced Rho-kinase activation in vitro. So this study examines whether EPA prevents cerebral vasospasm occurrence after SAH in patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yamaguchi University Hospital
• Collaborators: Iwate Medical University; Nakamura Memorial Hospital; Ootemachi Hospital; Tohoku University
• Treatments: Eicosapentaenoic acid ethyl ester

Criteria

Inclusion Criteria:

• Subarachnoid hemorrhage (SAH)

• The ruptured cerebral aneurysms conformed by cerebral angiography

• The patients with treated by craniotomy and clip application within 72h after the onset of SAH

Exclusion Criteria:

• Traumatic or mycotic aneurysms

• A history or complication of serious stroke

• Moya Moya disease

• A history of SAH

• Complication of serious heart or hepatic disease or infection or renal failure

• Malignant tumor

• Patients judged to be inappropriate by physician in charge